Cannabis Science Reports on Two Cannabis-Based Drug Release Programs
News Aug 13, 2009
Cannabis Science, Inc. announces that it has completed its review of the FDA licensing requirements and has made key progress with mapping out its initial cannabis drug medicines for FDA clinical trials.
The Company has determined it will have more than one product in clinical testing and trials at the same time. This news comes following the identification of two distinct parallel paths in developing pharmaceutical products for FDA approval. The first being the highly publicized H1N1 Swine flu and the deadly H1N5 Avian flu, and the second being a newly formed initiative for Veterans who suffer from Post Traumatic Stress Disorder (PTSD).
Together with these initiatives, Cannabis Science is laying a solid foundation for entrance into the FDA and other government regulatory agencies for developing medicines for Influenza, PTSD and other ailments.
The Company looks forward to announcing its continued progress with these initiatives through the development of an online progress chart that will become available at the www.cannabisscience.com website in the near future. This online tracking initiative will allow the general public immediate access to monitor each stage of development, submit questions, and request special circumstance information as we take our cannabis-based drugs to market.
Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., stated, “Times are changing. There is an ever-increasing demand for our cannabis-based drugs, and this demand is growing exponentially throughout the United States and the rest of the world. Modern science supports the public demand for cannabis-based FDA approved drug products that reduce the impact of critical life altering illnesses. The public need for our products drives our efforts to rapidly move our drugs through all available regulatory channels. We believe this enormous public demand on a global scale is a major key to our success and we are very excited to be positioned to provide solutions. We are currently sourcing cGMP compliant facilities to produce our initial formulations for FDA compliant testing.